MA48863A - TGF-BETA TYPE II RECEPTOR FUSION PROTEINS AND RELATED USES - Google Patents

TGF-BETA TYPE II RECEPTOR FUSION PROTEINS AND RELATED USES

Info

Publication number
MA48863A
MA48863A MA048863A MA48863A MA48863A MA 48863 A MA48863 A MA 48863A MA 048863 A MA048863 A MA 048863A MA 48863 A MA48863 A MA 48863A MA 48863 A MA48863 A MA 48863A
Authority
MA
Morocco
Prior art keywords
tgf
fusion proteins
receptor fusion
beta type
related uses
Prior art date
Application number
MA048863A
Other languages
French (fr)
Other versions
MA48863B1 (en
Inventor
Ravindra Kumar
Dianne S Sako
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Priority claimed from PCT/US2018/030816 external-priority patent/WO2018204594A1/en
Publication of MA48863A publication Critical patent/MA48863A/en
Publication of MA48863B1 publication Critical patent/MA48863B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA48863A 2017-05-04 2018-05-03 TGF-BETA RECEPTOR TYPE II FUSION PROTEINS AND RELATED USES MA48863B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762501229P 2017-05-04 2017-05-04
PCT/US2018/030816 WO2018204594A1 (en) 2017-05-04 2018-05-03 Tgf-beta receptor type ii fusion proteins and uses thereof

Publications (2)

Publication Number Publication Date
MA48863A true MA48863A (en) 2020-04-01
MA48863B1 MA48863B1 (en) 2023-08-31

Family

ID=88016828

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48863A MA48863B1 (en) 2017-05-04 2018-05-03 TGF-BETA RECEPTOR TYPE II FUSION PROTEINS AND RELATED USES

Country Status (1)

Country Link
MA (1) MA48863B1 (en)

Also Published As

Publication number Publication date
MA48863B1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
DK3280727T3 (en) SINGLE-ARMED TYPE I AND TYPE II RECEPTOR FUSION PROTEINS AND USES THEREOF
DK3628049T3 (en) TGF-BETA RECEPTOR TYPE-II FUSION PROTEINS AND USES THEREOF
MA44986A (en) GDF15 FUSION PROTEINS AND THEIR USES
DK3383916T3 (en) Anti-CD73 antibodies and uses thereof
KR102162129B9 (en) Anti-Galectin-9 Antibodies and Uses Thereof
MA51291A (en) MODIFIED IL-2 FC FUSION PROTEINS
MA46534A (en) FC HETERODIMERIC FUSION PROTEIN IL15 / IL15R
MA56480A (en) GLP-1 RECEPTOR AGONISTS AND THEIR USES
DK3292141T3 (en) FUSION PROTEINS
DK3458479T3 (en) ANTI-B7-H3 ANTIBODIES AND ANTIBODY-MEDICINE CONJUGATES
DK3365364T3 (en) Chimeric antibody/T cell receptor constructs and uses thereof
BR112017024757A2 (en) compositions and methods for reprogramming tcr using fusion proteins
BR112018004981A2 (en) anti-pro-myostatin / latent myostatin antibodies and uses thereof.
DK3180363T3 (en) SIRP-ALPHA-IMMUNOGLOBULIN FUSION PROTEINS
DK3307274T3 (en) ANTI-CD123 ANTIBODIES AND CONJUGATES THEREOF
DK3463435T3 (en) Alpha-synuclein antibodies and their uses
DK3532499T3 (en) ANTI-IL-33 Antibodies and Uses thereof
DK3402821T3 (en) PSMA-BINDING ANTIBODIES AND USES THEREOF
DK3606961T3 (en) GARP-TGF-BETA ANTIBODIES
DK3275895T3 (en) NEUROPILIN-1-SPECIFIC BINDING POPTIDE, FUSION PROTEIN FUSED THEREOF, AND ITS USE
MA50908A (en) VEGFR-FC FUSION PROTEIN FORMULATIONS
CL2016001921A1 (en) Immobilized proteins and their use
IL297395B1 (en) Btla fusion protein agonists and uses thereof
ZA202003845B (en) Fusion proteins
MA43715A (en) ANTI-TNF ANTIBODIES AND CORRESPONDING FUNCTIONAL FRAGMENTS